Variability tests for occult blood used by general practitioners in screening for colorectal cancer in the Czech Republic

Czech version

Authors: N. Král; B. Seifert; M. Korcová
Authors‘ workplace: Ústav všeobecného lékařství, 1. LF UK v Praze
Published in: Gastroent Hepatol 2015; 69(3): 255-258
Category: Gastrointestinal Oncology: Original Article
doi: https://doi.org/10.14735/amgh2015255

Overview

In 2009, innovations in colorectal cancer screening were made with the aim of achieving better results. Aside from stool guaiac tests, immunochemical tests with higher sensitivity and specificity were also introduced. With increasing adherence in the Czech population, however, there was also a significant increase in the number of positive immunochemical tests, which can lead to a fear of a higher number of false positives. In the Czech Republic, there has not yet been a survey published of the various types of immunochemical tests and their cut-off settings.

Key words:
screening – colorectal cancer – immunochemical test – general practitioner

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
6. 2. 2015

Accepted:
17. 5. 2015

Sources

1. Brenner H, Tao S. Superior diagnostic performance of faceal immunochemical tests for haemoglobin ina head- to- head comparison with guiac based faecal occult blood tests among 2235 participants of screening colonoscopy. Eur J Cancer 2013; 49: 3049– 3054. doi: 10.1016/ j.ejca.2013.04.023.

2. Guittet L, Guillaume E, Levillain G et al. Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2011; 20: 1492–1501. doi: 10.1158/1055-9965.EPI-10-0594.

3. Denters M, Deutekom M, Fockens Pet al. Implementation of population screen-ing for colorectal cancer by repeated fecal occult blood test in the Netherlands. BMC Gastroenterol 2009; 9: 28. doi: 10.1186/ 1471- 230X- 9- 28.

4. American College of Obstetricians and gynecologists. Committee Opinion No 482.Colonoscopy and colorectal cancer screening strategies. Obstet Gynecol 2011; 117(3): 766– 771. doi: 10.1097/ AOG.0b013e3182147930.

5. Menees SB, Inadomi J, Elta G et al. Colorectal cancer screening compliance and contemplation in gynecology patients. J Women Health 2010; 19(5): 911– 916.

6. Hol L, Wilschut JA, van Ballegooijen Met al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009; 100(7): 1103–1110. doi: 10.1038/sj.bjc.6604961.

7. Faivre J, Dancourt V, Lejeune C. Screening for colorectal cancer with immunochemical faecal occult blood tests. Dig Liver Dis 2012; 44(12): 967– 973. doi: 10.1016/ j.dld.2012.07.004.

8. Berchi C, Guittet L, Bouvier V et al. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening. Int J Technol Assess Health Care 2010; 26(1): 48– 53. doi: 10.1017/ S0266462309990808.

9. Kuipers EJ, Rösch T, Bretthauer M et al. Colorectal cancer screening- optimizing current strategies and new directions. Nat Rev Clin Oncol 2013; 10(3): 130– 142. doi: 10.1038/ nrclinonc.2013.12.

10. Kral N, Seifert B, Dušek L et al. Změny ve screeningu kolorektálního karcinomu – krok správným směrem? Onkologie 2010; 4(4): 251– 255.

11. Dusek L et al. Epidemiology, prevention and treatment of colorectal cancer based on available studies and data. Prague: University Hospital Motol 2012.

12. Zavoral M, Fric P, Suchanek S et al. Národní program screeningu sporadického kolorektálního karcinomu (KR-CA): vývoj, současnost, perspek. Lékařské listy 2013: 16–18.

13. von Wagner C, Semler C, Good A et al. Health literacy and self- efficacy for participating in colorectal cancer screening: the role of information processing. Patient Educ Couns 2009; 75(3): 352– 357. doi: 10.1016/ j.pec.2009.03.015.

14. Jepson RG, Hewison J, Thompson A et al. Patient perspective on information and choice in cancer screening: a qualitative study in UK. Soc Sci Med 2007; 65(5): 890– 899.

15. Weller DP, Patnick J, McIntosh H et al. Uptake in cancer Screening programmes. Lancet Oncol 2009; 10(7): 693– 699. doi: 10.1016/ S1470- 2045(09)70145- 7.

16. von Karsa L, Patnick J Segnan N et al. European Colorectal Cancer Screening Guidelines Working Group. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 2013; 45(1): 51– 59. doi: 10.1055/ s- 0032- 1325997.

17. Segnan N, Patnick J, von Karsa L. European guidelines for quality assurance in colorectal cancer screening and diagnosis. 1st ed. Luxembourg: Publications Office of the European Union 2010.

18. Sakata N, Sakata Y, Shimoda R et al. Repeated screening with fecal immunochemical tests reduced the incidence of colorectal cancers in Saga, Japan. Hepatogastroenterology 2014; 61(133): 1224– 1228.

19. Stock C, Ihle P, Schubert I et al. Colonoscopy and fecal occult blood test use in Germany: results from a large insurance-based cohort. Endoscopy 2011; 43(9): 771– 781. doi: 10.1055/ s- 0030- 1256504.

20. Weller D, Coleman D, Robertson Ret al. The UK colorectal cancer screening pilot: results of the second round of screening in England. Br J Cancer 2007; 97(12): 1601– 1605.